Recursion Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-11-05
- Employees
- 500
- Market Cap
- $2.1B
- Website
- http://www.recursion.com
- Introduction
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.
How AI is transforming drug discovery
AI is revolutionizing drug discovery, enabling faster identification of failures and novel drug targets. Companies like Recursion, Benevolent AI, and Lantern Pharma leverage AI for precision oncology and new molecule development, significantly reducing time and costs. Despite challenges, AI's potential to improve clinical trial success rates and efficiency is immense, with big pharma increasingly adopting AI technologies.
How Generative AI Is Accelerating Drug Discovery
Generative AI, leveraging Large Language Models, is revolutionizing drug discovery by decoding biological and chemical languages, speeding up development, and reducing costs. It aids in target identification, lead generation, and optimization, enabling faster progression to clinical trials. Companies like Insilico Medicine have significantly cut costs and time, showcasing AI's transformative potential in healthcare.
Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months
Recursion Pharmaceuticals advances drug discovery with AI/ML, delivering data to Bayer and initiating a joint oncology project. Bayer to beta-test LOWE for drug development. Recursion updates pipeline with seven clinical trial readouts expected within 18 months, leveraging its platform for high-throughput experiments and predictive modeling.
7 Powerful Examples of Artificial Intelligence in Healthcare
AI is transforming healthcare through diagnostics, precision medicine, virtual nursing, robotic surgery, predictive analytics, administrative efficiency, and medical research. It enhances diagnostic accuracy, personalizes treatments, supports patients, improves surgical precision, predicts health risks, streamlines operations, and accelerates drug discovery, aiming to augment human intelligence for better patient care.
How Generative AI is Accelerating Drug Discovery
Generative AI, leveraging Large Language Models, is revolutionizing drug discovery by decoding biological and chemical languages, enabling faster, cost-effective development of new drugs. It aids in target identification, lead generation, and optimization, significantly reducing time and costs. Companies like Insilico Medicine exemplify its transformative impact, promising quicker cures and better healthcare outcomes.
Recursion Pharmaceuticals CEO explains how AI could make drug development faster and less costly
Recursion Pharmaceuticals CEO Chris Gibson shared how AI and machine learning are revolutionizing drug development, making it faster and cheaper. With a $50M investment from Nvidia, Recursion analyzes vast data to discover new treatments, notably for rare diseases like cerebral cavernous malformation, aiming to reduce development time and cost significantly.
Recursion Provides Business Updates and Reports First Quarter 2024 Results
Recursion reported Q1 2024 updates, including Phase 2 clinical trials progress, BioHive-2 supercomputer benchmarking, and a Helix partnership for AI model training. They also announced financial results, with a net loss of $91.4M, and plans for future trials and collaborations.
Recursion obtains FDA approval for AI-discovered cancer treatment
Recursion's REC-1245, a novel RBM39 degrader for treating biomarker-enriched solid tumours and lymphoma, received FDA IND clearance for Phase 1/2 trials. Targeting over 100,000 patients in the US and EU5, it aims to address treatment-resistant tumours, with trials expected to start in late 2024.
Causaly, an AI platform for drug discovery and biomedical research, raises $60M
Causaly, a London AI startup, raised $60M in Series B funding led by ICONIQ Growth, totaling $93M. Its platform accelerates drug discovery, reducing development time from 10-15 years to several, and is used by major pharmaceutical companies. Unlike others, Causaly focuses on providing tools for drug discovery rather than developing therapeutics.
Revolutionizing clinical trials: the role of AI in accelerating drug development
AI revolutionizes clinical trials by enhancing data collection, patient recruitment, and analysis, reducing time and costs. It enables personalized medicine, improves efficiency, and accelerates drug development, despite challenges like data quality and ethical concerns.
© Copyright 2025. All Rights Reserved by MedPath